SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY

Stefan Schreiber  ¹     Mamoru Watanabe  ²     Chohee Yun  ³     Yan Zhou     Sally Zhao     Jeremy Hsieh     Ulrik Moerch  ⁴     Gerhard Rogler  ⁵     Edward V Loftus Jr  ^6    
1 University Hospital Schleswig-Holstein, Kiel, Germany
² Tokyo Medical and Dental University, Tokyo, Japan
³ Gilead Sciences, Inc., Foster City, United States
⁴ Gilead Sciences, Inc., Copenhagen, Denmark
⁵ University of Zurich, Zurich, Switzerland
⁶ Mayo Clinic College of Medicine, Rochester, Minnesota, United States

Topic
IBD, Paediatrics

Session
IBD epidemiology and drug safety

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)